FDA approves Xtandi for non-metastatic CRPC

FDA approved an sNDA for Xtandi enzalutamide from Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) to treat non-metastatic castration-resistant prostate cancer (CRPC). The oral androgen receptor antagonist is already approved to treat metastatic CRPC...